Recent News

• 11.13.2025 - Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
• 11.06.2025 - Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.30.2025 - Cartesian Therapeutics Announces New Employment Inducement Grants
• 10.30.2025 - Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
• 10.03.2025 - Cartesian Therapeutics Announces New Employment Inducement Grant
• 08.28.2025 - Cartesian Therapeutics to Participate in Upcoming Investor Conferences
• 08.07.2025 - Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 8-K Current report
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2025 - 3 Initial statement of beneficial ownership of securities